Literature DB >> 28243080

MiR-344b-1-3p targets TLR2 and negatively regulates TLR2 signaling pathway.

Hong Xu1, Yuting Wu2, Li Li1, Weifeng Yuan1, Deming Zhang2, Qitao Yan3, Zhenhui Guo3, Wenjie Huang1.   

Abstract

OBJECTIVES: COPD is an abnormal inflammatory response characterized by decreased expression of TLR2 in patients, which is suggested to induce invasive pulmonary aspergillosis (IPA). MicroRNAs (miRNAs) have been shown to play important roles in the pathogenesis of human respiratory system disorders. Therefore, the aim of this study was to identify the miRNAs involved in the regulation of TLR2 signaling in COPD.
MATERIALS AND METHODS: miRNA microarray analysis was performed to screen for the dysregulated miRNAs in alveolar macrophages (AMs) isolated from COPD rats. The interaction between these miRNAs and TLR2 gene was predicted using miRBase and validated using dual luciferase assay. Based on the analysis, a novel miR-344b-1-3p was identified as a novel modulator of TLR2 gene. Then, the mechanism through which miR-344b-1-3p regulated TLR2 expression was explored using cigarette smoke extract (CSE)-pretreated NR8383 cells. Moreover, by subjecting CSE-pretreated NR8383 cells to Pam3CSK4, the effect of miR-344b-1-3p on NF-κB activity and other important mediators of COPD, including IRAK-1, ERK, TNF-α, IL-1β, and MIP-2, was also assessed.
RESULTS: COPD rat model was successfully induced by smoke inhalation. Among the 11 upregulated miRNAs in AMs from COPD rats, miR-344b-1-3p was predicted to be a novel miRNA targeting TLR2 gene. In the CSE pretreated NR8383 cells exposed to Pam3CSK4, miR-344b-1-3p inhibition increased the expression levels of TLR2, TNF-α, and IL-1β and decreased the expression levels of MIP-2. In addition, the phosphorylation of IRAK-1, IκBα, and IRK was augmented by miR-344b-1-3p inhibition.
CONCLUSION: Findings outlined in this study suggest that miR-344b-1-3p was an effective modulator of TLR2 gene, which can be employed as a promising therapeutic and preventive target of IPA in COPD patients.

Entities:  

Keywords:  COPD; TLR2; invasive pulmonary aspergillosis; miR-344b-1-3p

Mesh:

Substances:

Year:  2017        PMID: 28243080      PMCID: PMC5317246          DOI: 10.2147/COPD.S120415

Source DB:  PubMed          Journal:  Int J Chron Obstruct Pulmon Dis        ISSN: 1176-9106


Introduction

COPD ranks the fourth of all the causes of morbidity and mortality in the third world countries and is predicted to be the third leading cause of death in the third world countries by the year 2020.1 The disease is characterized by T-cell chronic inflammatory response and increased susceptibility to microbial infection, which markedly contributes to exacerbations and decline of lung function.2,3 As a widely distributed infectious microbe species, Aspergillus spp., have become a severe threat for COPD patients who are impaired by abnormal immune function, resulting in invasive pulmonary aspergillosis (IPA).4,5 Worse still, COPD patients attacked by IPA are always exposed to a higher chance of mortality. Therefore, early intervention of the disorder is critical for better prognosis of IPA in patients with COPD. Generally, macrophages function as key defense against pathogens, which contribute to inflammation and tissue injury as well as control and resolution of inflammation. In COPD, the number of alveolar macrophages (AMs) increases with the disease severity, but these newly generated cells are always functionally defective.6–8 It has been demonstrated that the phagocytic activity was significantly reduced in AMs from COPD. This is suggested to be attributed to the impaired action of pathogen recognition and anti-inflammation in AMs. The innate immune recognition of pathogens by macrophages is mediated by pathogen recognition receptors. Among these receptors, TLR2 plays important roles in the recognition and removal of Aspergillus species by activating immune responses and phagocytosis of macrophages. As previously reported, AMs from smokers with and without COPD express less TLR2 than nonsmokers,9 which will result in the change of the subsequent intracellular signaling. The diminished TLR2 expression may lead to reduced identification and removal of pathogens and facilitate microbial colonization as well as increased risk of IPA.10 Previous study in our laboratory suggested that after Aspergillus spore transplantation, the upregulated extent of TLR2 in AMs from COPD rats was dramatically smaller than that in normal rats, whereas the increased extent of TLR2 mRNA in AMs from COPD rats was larger than that in normal rats.11 Taken together, this might indicate that transcription of TLR2 was not impaired even with the attack of COPD in rat models. However, the mechanism affecting the protein expression of TLR2 needs further elucidation. MicroRNAs (miRNAs) are a class of evolutionarily conserved small RNAs, which regulate target gene expression by binding to the 3′-UTR end of target mRNA.12 Hundreds of miRNAs have been identified in plants, animals, and viruses. For Homo sapiens, >700 miRNA genes have been reported and comprehensively studied, including those involved in immune responses and COPD.13 Moreover, several miRNAs have shown their potential as regulators of TLR2 signaling transduction. In human promonocyte THP-1 cells, miR-146a is induced by lipopolysaccharide (LPS) stimulation and negatively regulates TLR2 signaling pathway, contributing to tolerance during microbial infection and sepsis. However, the regulation of TLR2 expression by miRNA in COPD patients still remains unknown. Thus, in this study, the functional link between TLR2 and miRNAs in COPD was selected as the research focus. With a series of in vivo and in vitro assays, the results first demonstrated that miR-344b-1-3p was an important regulator of TLR2. Regulation of the miRNA would not only influence the TLR2 signaling activation but also affect the expression of inflammatory mediators.

Materials and methods

Chemicals and instruments

Coco cigarettes were purchased from Guangdong Tobacco Industry Co. Ltd., (Guangdong, People’s Republic of China). Culture medium (RPMI-1640), fetal bovine serum (FBS), and TRIzol were purchased from Thermo Fisher Scientific Corporation (Carlsbad, CA, USA). The 2× polymerase chain reaction (PCR) master mix was purchased from Arraystar (Rockville, MD, USA). Other chemicals were commercially available and purchased as reagent grade from Sinopharm (Shanghai, People’s Republic of China).

Animals and induction of COPD model by smoke exposure

Sixty male Wistar rats (12 weeks old, weighing 230–250 g) were obtained from Southern Medical University (Guangzhou, People’s Republic of China) and fed in the specific pathogen free (SPF) animal room of Southern Medical University and housed in box cages (<6 rats in every cage) at 23°C±3°C and 55%±10% humidity with a 12-hour light/12-hour dark cycle. All animal experiments were approved by the ethic committee of Southern Medical University (Certificate no 440020100002199). All animal-handling procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and followed the guidelines of the Animal Welfare Act. After a 3-day adapting period, all animals were randomly divided into two groups (n=30 in each group) and COPD condition was induced as follows: 1) COPD model group: in a home-made smoking box (110×80×75 cm), the rats were exposed to cigarette smoke generated from Yeshu cigarettes twice daily (30 minutes each time) with an interval of 8 hours for 90 days, and 2) control group: rats were subjected to saline tracheal instillation twice daily for 90 days.

COPD pulmonary function detection, CT examination, and histopathology assays

Assessment of pulmonary function is essential for the diagnosis and characterization of COPD. Spirometry was used to detect airway obstruction. The primary parameters of diagnostic assessment are minute ventilation volume (MVV), inspiratory resistance (Ri), peak expiratory flow (PEF), and forced expiratory volume in 0.3 second (FEV0.3). After anesthesia by intraperitoneal injection of pentobarbital sodium (30 mg/kg body weight), the rats were examined by CT test (Aloka LaTheta LCT-200; Hitachi-Aloka Medical, Ltd, Tokyo, Japan) to determine COPD. After infusion for macrophage isolation, the left lungs were sampled and fixed in 10% neutral formalin solution for 48 hours. Following gradient dehydration with ethanol, the lungs were embedded in paraffin for the preparation of 4 μm-thick sections. Sections were stained with hematoxylin and eosin (H&E) using standard pathology procedures and evaluated by a pathologist blinded to the study as described previously.14,15

AM isolation and identification

Rats were anesthetized by intraperitoneal injection of pentobarbital sodium (30 mg/kg body weight). The chest of each rat was opened, and the bronchi lobaris inferior sinister was clipped. The lungs were infused with 8 mL of phosphate buffer saline (PBS) at 37°C four times via the main trachea. The alveolar lavage fluid was centrifuged at 1,000 rpm and 4°C for 10 minutes. The supernatant was subsequently discarded, and the pellet was washed twice with PBS, for 10 minutes each time. The cells were then incubated in six-well plates (1 mL/well; 1×106 cells/mL) with cover glasses in 1 mL RPMI-1640 with 10% FBS. After 2-hour culture under 5% CO2 at 37°C, the unattached cells were removed by washing with PBS three times. Using Wright–Giemsa staining and immunofluorescence staining of CD68, the macrophages were identified.

Total RNA isolation and reverse transcription

The preparation and evaluation of AMs was conducted routinely. Total RNA was extracted using TRIzol and miRNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol, except that isopropanol was replaced with ethanol for RNA precipitation. RNA quality was ascertained using 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Then 1 μg of total RNA was reverse transcribed, and the product (11 μL) was preamplified using Megaplex PreAmp Primers and DBI Bestar® qPCR RT Kit (Applied Biosystems, Foster City, CA, USA) in a 20 μL PCR. The preamplification cycling conditions were 37°C for 60 minutes and 98°C for 10 minutes. The preamplified cDNA was diluted with 0.1× Tris-EDTA buffer (pH 8.0) to 10 μL, and then 1 μL of diluted cDNA was used in each plate for real-time PCRs (RT-PCRs).

miRNA microarray analysis

RNA samples from three randomly selected rats in each group were used for miRNA microarray analysis. After RNA quantification using a NanoDrop spectrophotometer, the samples were labeled using the miRCURY™ Hy3™/Hy5™ Power Labeling Kit and hybridized to the miRCURY LNA™ Array (v.18.0). The samples were hybridized using a hybridization station, and the arrays were scanned with the Axon GenePix 4000B Microarray Scanner. The raw intensity of the image was read using GenePix Pro V6.0. The intensity of the green signal was calculated after background subtraction, and four replicated spots for each probe on the same slide were averaged. MiRNAs with intensity ≥30 in all samples after background correction were used to calculate the normalized factor. The median normalization method was used to normalize the expressed data. After normalization, significantly differentially expressed miRNAs were identified via volcano spot filtering. Subsequently, clustering analysis was performed with the MeV software (v4.6, J. Craig Venter Institute, Rockville, MD, USA), and two-dimensional tree-shaped heat map was acquired.

Bioinformatics analysis

The target genes of the target miRNA were crossly predicted by TargetScan (http://www.targetscan.org/), miRBase (http://www.mirbase.org/index.shtml), and miRanda (http://www.microrna.org/microrna/home.do). Then, the functional gene ontology (GO) biological processes, in terms of the putative targets of candidate miR-34b-1-3p and its target gene TLR2, as well as the Kyoto Encyclopedia of Genes and Genomes pathway analysis were performed by the Database for Annotation, Visualization and Integrated Discovery. For each GO score, the P-value of the function enrichment and the P-value of Benjamini correction were calculated.

Quantitative RT-PCR analysis of miRNAs

Real-time quantification was performed using an Applied Biosystems 7500 Sequence Detection System. The 20 μL PCR included 1 μL RT product (1:5 dilution), 0.5 μL universal reverse primer, 0.5 μL of sense primer, and 10 μL mix buffer (DBI Bestar® SybrGreen qPCR mastermix). The reactions were incubated in a 96-well optical plate at 94°C for 2 minutes, followed by 40 cycles of 94°C for 20 seconds, 58°C for 20 seconds, and 72°C for 20 seconds. All reactions were performed in triplicate. All primers used are listed in Table 1.
Table 1

Primer pairs of miRNA used for the RT-PCR

GeneTopBottom
rno-miR-146a-5p5′-GGGTGAGAACTGAATTCC-3′5′-TGCGTGTCGTGGAGTC-3′
rno-miR-19b-3p5′-GGGGGGTGTGCAAATCC-3′5′-GTGCGTGTCGTGGAGTCG-3′
rno-miR-124-3p5′-GGGTAAGGCACGCGGT-3′5′-GTGCGTGTCGTGGAGTCG-3′
rno-miR-363-5p5′-GCGGGTGGATCACGATG-3′5′-GTGCGTGTCGTGGAGTCG-3′
rno-miR-9a-3p5′-GGGGGGATAAAGCTAGATAACC-3′5′-GTGCGTGTCGTGGAGTCG-3′
rno-miR-344b-1-3p5′-GGGGTGATATAACCAAAGCC-3′5′-GTGCGTGTCGTGGAGTCG-3′
rno-miR-125b-5p5′-GCTCCCTGAGACCCTAAC-3′5′-CAGTGCGTGTCGTGGAGT-3′

Abbreviations: miRNA, microRNA; RT-PCR, real-time polyerase chain reaction.

Plasmid construction

The constructed plasmids (psiCHECK™-2-TLR2-3′UTR/psiCHECK™-2-TLR2-3′UTR-R) contained 3′-UTR promoter of TLR2 gene and were purchased from Sangon (Shanghai, People’s Republic of China).

Luciferase assay

Human 293 cell line (ATCC, Manassas, VA, USA) was maintained in RPMI-1640 with 10% heat inactivated FBS, supplemented with 1% antibiotic–antimycotic solution (Thermo Fisher Scientific Corporation) at 37°C in a humidified atmosphere of 95% air and 5% CO2. Then, cells were seeded at a density of 2.0×104 cells/mL in 24-well plates to achieve ~70% confluence and were transfected with psiCHECK™-2-TLR2-3′UTR/psiCHECK™-2-TLR2-3′UTR-R plasmids and miR-344b-1-3p inhibitors using Lipofectamine 2000 (Thermo Fisher Scientific Corporation). 293 cells were incubated for an additional 36 hours after transfection. Thereafter, cells were collected and further assayed for firefly luciferase activity using the Dual-Luciferase® Reporter Assay System (Promega, Madison, WI, USA) according the manufacturer’s instruction. The results were recorded using a Synergy™ 4 Microplate Reader (BioTek, Winooski, VT, USA).

Coco cigarette smoke extract (CSE)

CSE was prepared by combusting two coco cigarettes purchased from Guangdong Tobacco Industry Co., Ltd (filters removed) using a peristaltic pump (Watson Marlow 323 E/D) and passing the smoke through 25 mL of FBS-free Dulbecco’s Modified Eagle Medium supplemented with penicillin, streptomycin, and amphotericin B at a rate of 5 minutes/cigarette. The obtained solution is referred to as 100% strength.

Cell treatment

Rat NR8383 cell line (Type Culture Collection of Chinese Academy of Sciences, Beijing, People’s Republic of China) was maintained in RPMI-1640 with 10% heat-inactivated FBS and 1% antibiotic–antimycotic solution (Thermo Fisher Scientific Corporation) at 37°C in a humidified atmosphere of 95% air and 5% CO2. NR8383 cells were seeded in a 24-well plate at the density of 1.0×104 cells/mL and then treated with 0%, 5%, 10%, and 15% CSE. To select the optimal concentration of CSE for the following exposure, NR8383 cells were exposed to 0%, 5%, 10%, and 15% CSE for 24 hours. Subsequently, the expression level of miRNA-344b-3p and the apoptosis of NR8383 cells under different CSE treatments were determined by RT-PCR and flow cytometry, respectively. After treatment with 10% CSE for 24 hours, miR-344b-1-3p inhibitor and null inhibitor were transfected into NR8383 cells through lentiviral transfection. Subsequently, the transfected cells were exposed to 1 μg/mL of Pam3CSK4 for an additional 24 hours before harvesting. We also seeded NR8383 cells with CSE and Pam3CSK4 treatment as control.

Flow cytometry assay

Using flow cytometry (Epics XL; Beckman Coulter, Brea, CA, USA), the apoptosis of NR8383 cells after exposure to different concentrations of CSE was analyzed using Annexin V and propidium iodide (PI) staining (eBioscience, Hatfield, UK). TLR2 expression on the NR8383 cells was determined using flow cytometry by staining with fluorescence-conjugated anti-TLR2. Data acquisition and analysis were performed using CellQuest software.

Western blotting analysis

To evaluate the effect of miR-344b-1-3p on NF-κB signaling, the protein levels of IκBα were determined in NR8383 cells exposed to Pam3CSK4. The concentration of protein extracts from NR8383 was determined using a BCA Kit (Pierce, Rockford, IL, USA), and 20 μg of protein lysates were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by transfer to nitrocellulose membranes. Western blotting analysis was performed regularly, and the signal was detected using an ECL system (Millipore, Billerica, MA, USA). Antibodies used in this study were anti-rat p-IRAK-1 (1:5,000; Abcam, Cambridge, UK), anti-rat p-IκBα (1:20,000; Millipore), and anti-rat p-ERK (1:10,000; Millipore).

Enzyme-linked immunosorbent assay (ELISA)

The concentrations of TNF-α, IL-1β, and MIP-2 in the culture medium were quantified using a commercial rat inflammatory factor heterodimer ELISA kit (BioLegend, San Diego, CA, USA) according to the manufacturer’s protocol. All samples were assayed in duplicate. The mean concentration was determined for each sample. The sensitivity of the assay is 0.13±0.01 ng/mL. The color reaction was stopped with 50 μL of 1 M HCl per well, and the optical density was measured after 1 hour at 492 nm (OD492) on an Infinite® M200 microtiter plate reader (Tecan, Maennedorf, Switzerland).

Statistical analysis

All the data were expressed in the form of mean ± SD, and each assay was represented by three replicates (n=3). Post doc multiple comparisons after ANOVA were performed by Duncan method to control type I error. Difference between two groups was analyzed using Student’s t-test. Significance was accepted when two-tailed P-value was <0.05. All the statistical analyses and graph manipulation were conducted using the Statistical Package for the Social Sciences Version 19.0 (IBM, Armonk, NY, USA).

Results

Morphology analysis of COPD rats

As listed in Table 2, the levels of expiratory resistance and inspiratory resistance were increased in the COPD group when compared with the control group, and the difference was statistically significant (P<0.05). On the contrary, FEV0.3/FVC in the COPD group was decreased when compared with those in the control group (P<0.05). These results indicated that the pulmonary function was impaired in the COPD rats. Lungs from rats in the COPD group displayed more lesions. The CT analysis results showed that the transparency was increased in the rats exposed to the cigarette smoke when compared with that in the healthy rats (Figure 1A). In addition, hyperplasia of ciliated columnar epithelial cells, loss of cilia, thinning of alveolar walls, bronchial effusion, infiltration of inflammatory cells, enlargement of alveolus cavity, and generation of pulmonary bulla were observed in the rats exposed to cigarette smoke (Figure 1B). All these results indicated that the COPD model was successfully developed.
Table 2

The results of lung function tests analysis (n=5, mean ± SD)

ParameterControlCOPDTP-value
MVV (mL)111.04±2.92108.8±2.860.9600.392
Re (kPa s/L)27.00±0.8451.32±2.97*−15.7730.000
Ri (kPa s/L)26.70±1.5243.10±1.80*−16.1670.000
PEF (mL/s)21.46±1.6520.42±1.075.7700.494
FEV0.3/FVC (%)87.40±0.9177.58±1.76*9.5410.001

Note:

P<0.05 versus control group.

Abbreviations: FEV0.3, forced expiratory volume in 0.3 second; MVV, minute ventilation volume; PEF, peak expiratory flow; Re, expiratory resistance; Ri, inspiratory resistance; SD, standard deviation.

Figure 1

CT analysis and histopathology examination of COPD rats.

Notes: The rats were treated with cigarette smoke and saline tracheal instillation for 90 days. Coronal CT images obtained in the control group (A) and in the COPD group (B). Histological examination of lungs in control-treated rats (C) and cigarette smoke-treated rats (D).

Differentially expressed miRNAs in AMs of COPD rats

MiRNA expression profiling studies were conducted in AM samples using the miRCURY LNA™ microRNA Array (v.8.0). A total of 13 miRNAs in AMs were identified with a more than twofold change in the levels between the COPD and control groups (Figure 2A). Among all detected miRNAs with miRNA microarray, seven members were predicted to target TLR2 analyzed by miRBase, miRanda, and miRDB databases.
Figure 2

Expression profile and validation of selected miRNAs in AMs from COPD rats.

Notes: (A) miRNA arrays of AMs. The expression change indicated by the color bar was calculated by comparing the miRNA expression levels in AMs from COPD rats with those in control. Only differentially expressed miRNAs pass fold change filtering (≥2-fold change). The values presented are the mean of triplicate samples. (B) Comparison of expression levels of seven differentially expressed miRNAs in microarray and real-time PCR assay. Data are presented as mean ± SD of three independent tests with triplicate samples. The miRNA expression was normalized against an endogenous U6 RNA control.

Abbreviations: AMs, alveolar macrophages; miRNA, microRNA; qPCR, quantitative polymerase chain reaction; PCR, polymerase chain reaction; SD, standard deviation.

In order to confirm the results obtained from the miRNA microarray, the expression levels of seven miRNAs were analyzed by RT-PCR in the samples analyzed on the microarray. Consistent with the results from the miRNA microarray, the miRNAs, including miR-344b-1-3p, were differentially expressed between the COPD and control groups (Figure 2B). Furthermore, miR-344b-1-3p, miR-125b-5p, and miR-146a-5p levels in COPD AMs were significantly higher than those in control.

TLR2 is a direct target of miR-344b-1-3p

In reference to the significantly induced expression in COPD rats, there are no reports about the relationship between miR-344b-1-3p and TLR2; therefore, this miRNA was selected as the candidate for further studies. Based on the result of luciferase assay, only treatment with both miR-344b-1-3p inhibitor and psiCHECK™-2-TLR2-3′UTR decreased the luciferase activity in 293 cells (Figure 3), representing the direct interaction of miR-344b-1-3p on TLR2 gene transcription.
Figure 3

TLR2 is a direct target of miR-344b-1-3p.

Notes: psiCHECKTM-2 luciferase construct containing a WT or MUT TLR2-3′-UTR was cotransfected with NC, miR-344b-1-3p, NC inhibitor, or miR-344b-1-3p inhibitor. All experiments were repeated independently three times. Significant difference, **P<0.01.

Abbreviations: WT, wild type; MUT, mutated; miRNA, microRNA; hsa, homo sapien; NC, negative control.

Detection of miR-344b-1-3p in vitro by RT-PCR

To select the optimal CSE concentration of subsequent assays, the apoptosis of NR8383 cells after treatment with CSE of different concentrations was detected. As shown in Figure 4, NR8383 cell apoptosis rate in all the three CSE treated groups was higher than that in the control group, and the difference was statistically significant (P<0.05). The strongest effect to induce cell apoptosis was observed in 10% CSE group, which was selected for further experiments. Moreover, the expression of miR-344b-1-3p was analyzed by RT-PCR in NR8383 cells to explore the effect of CSE on miR-344b-1-3p expression. It was found that in NR8383 cells subjected to 5% and 10% CSE treatments, the levels of miR-344b-1-3p were upregulated when compared with the control group, and the differences were statistically significant (P<0.01) (Figure 5). However, when the concentration of CSE increased to 15%, the level of miR-344b-1-3p was dramatically decreased when compared with that in the 10% CSE group (Figure 5). Therefore, it was concluded by these findings that CSE could induce the activity of miR-344b-1-3p in NR8383 cells, which could be employed for the establishment of COPD condition in vitro. The strongest effect was observed when the concentration of CSE was 10%, which confirmed the results of flow cytometry.
Figure 4

Effect of CSE on NR8383 cell apoptosis.

Notes: (A) Dot plots and (B) histogram of NR8383 cells exposed to CSE at 5%, 10%, 15% and 0% for 24 hours before being harvested for apoptosis test. The detection was repeated independently three times. Significantly different from the control group: *P<0.05, **P<0.01, ***P<0.001.

Abbreviations: CSE, cigarette smoke extract; PI, propidium iodide; FITC, fluorescein isothiocyanate.

Figure 5

Effect of CSE on miR-344b-1-3p expression as detected by real-time PCR.

Notes: MiR-344b-1-3p level was detected after 24-hour exposure to CSE at the concentrations of 0%, 5%, 10%, and 15%. The detection was repeated independently three times. Significantly different from the control group, **P<0.05. ***P<0.01.

Abbreviations: CSE, cigarette smoke extract; miRNA, microRNA; PCR, polymerase chain reaction.

Effect of miR-344b-1-3p on TLR2 and downstream signaling transduction

As shown in Figure 6, the TLR2 level was increased after inhibiting miR-344b-1-3p. To determine the effect of miR-344b-1-3p on inflammatory responses of NR8383 cells induced by TLR2, the levels of TNF-α, IL-1β, and MIP-2 in supernatant were evaluated. Results of ELISA are shown in Figure 7A–C. The levels of TNF-α, IL-1β, and MIP-2 were significantly increased after inhibiting miR-344b-1-3p.
Figure 6

Effect of miR-344b-1-3p on TLR2 expression in NR8383 cells exposed to 10% CSE.

Notes: (A) Quantitative analysis results of RT-PCR validation of TLR2 mRNA levels. The expression of miR-334b-1-3p suppressed the activity of TLR2 even with the administration of TLR2 agonist. Once miR-334b-1-3p was suppressed, the expression of TLR2 was induced. Significantly different from the control group, *P<0.05. (B) Representative images of flow cytometry validation of TLR2 protein expression. A, 10% CSE-treated NR8383 cells administrated with miRNA-344b-1-3p inhibitor and 1 μg/mL of Pam3CSK4; B, 10% CSE-treated NR8383 cells administrated with control inhibitor and 1 μg/mL of Pam3CSK4; C, 10% CSE-treated NR8383 cells administrated with 1 μg/mL of Pam3CSK4.

Abbreviations: CSE, cigarette smoke extract; GAPDH, reduced glyceraldehyde-phosphate dehydrogenase; miRNA, microRNA; RT-PCR, real time polymerase chain reaction; FITC, fluorescein isothiocyanate.

Figure 7

Effect of miR-344b-1-3p inhibitor on the expressions or phosphorylation of downstream proteins of TLR2 in vitro.

Notes: The levels of (A) TNF-α, (B) IL-1β, and (C) MIP-2. The expression of miR-334b-1-3p suppressed the activity of all the indicators even with the administration of TLR2 agonist. Once miR-334b-1-3p was suppressed, the expression of those indicators was induced. (D) Representative images of Western blotting of p-IκBα, p-IRAK-1, and p-ERK. GAPDH functioned as a reference protein. (E) The quantitative analysis results of western blotting of p-IκBα, p-IRAK-1, and p-ERK. A, 10% CSE-treated NR8383 cells administrated with miRNA-344b-1-3p inhibitor and 1 μg/mL of Pam3CSK4; B, 10% CSE-treated NR8383 cells administrated with control inhibitor and 1 μg/mL of Pam3CSK4; C, 10% CSE-treated NR8383 cells administrated with 1 μg/mL of Pam3CSK4. **P<0.01, ***P<0.001.

Abbreviations: CSE, cigarette smoke extract; GAPDH, reduced glyceraldehyde-phosphate dehydrogenase; miRNA, microRNA.

Furthermore, the phosphorylation levels of IκBα, IRAK-1, and ERK in NR8383 cell line pretreated with CSE were augmented following transfection of miR-344b-1-3p inhibitor (Figure 7D and E).

Discussion

It is well known that patients with severe COPD are at higher risk of developing IPA.16 This has been increasingly accepted to be associated with the decreased activity of AMs. TLR2 is the first pattern recognition receptor identified as the cell-activating receptor for Gram-negative lipopolysaccharides, as well as the receptor for both Gram-positive and Gram-negative bacteria, mycobacteria, Mycoplasma, and yeast.17 In addition to the functions mentioned earlier, recent study has shown that TLR2 deficiency induced a high risk for succumbing to IPA,9 which further confirms the key role of TLR2 in the innate immune system of mammalians. In this study, for the first time, we report that miRNA-344b-1-3p plays a pivotal role in the downregulation of TLR2 in lung AMs, indicating that decreased TLR2 expression induced by miRNAs might result in the high sensitivity of patients with COPD to Aspergillus species. Emerging reports elaborate that the abnormal expression of some miRNAs is an important regulator of inflammatory responses and lung diseases.18–20 As it has been proved that TLR2 is the target of several miRNAs, including miR-105, miR-19, miR-1225-5P, miRNA-143, miRNA-154, and miR-UL112-3P, in a variety of cell lines,21–25 it is reasonable to observe the association of miRNAs with TLRs in COPD AMs. To fulfill such a purpose, in this study, COPD was induced in rats by smoke exposure. It was found that cigarette smoke exposure decreased FEV0.3/FVC and increased pulmonary transparency. In addition, rats exposed to cigarette smoke showed typical changes of COPD, including hyperplasia of ciliated columnar epithelial cells, thinning of alveolar walls, enlargement of alveolus cavity, and generation of pulmonary bulla. Using the analysis of microarray chips and the validation of RT-PCR in this study, we confirmed that production of miR-344b-1-3p in COPD AMs was significantly enhanced compared to that in the control group. Using dual luciferase assay, the targeting relationship between miR-344b-1-3p and TLR2 was confirmed as well. The above findings showed that miR-344-b-1-3p played an important role in the post-transcriptional regulation of TLR2 and might be involved in the onset of IPA in COPD. As previously reported, miR-344b-1-3p is capable of activating Wnt/β-catenin signaling and inhibiting adipocyte differentiation, which is associated with renal disease.26 In this study, its involvement in immunity was observed for the first time. To observe the functional effect of miR-344b-1-3p on the regulation of TLR2-related signaling, we examined whether TLR2 agonist, Pam3CSK4, could affect the function of miR-344b-1-3p in the activation of NF-κB pathway. NF-κB is usually in the inactive state by its inhibitory protein, IκB. The phosphorylation of IκBα allows NF-κB to initiate the functionality. It has been reported that NF-κB plays an important role in macrophage phagocytic activity and upregulates the production of proinflammatory cytokines.27 In this study, the data showed that the level of p-IκBα in the NR8383 cells exposed to CSE was upregulated after inhibition of miR-344b-1-3p, indicating that this miRNA was involved in the decreased NF-κB function by suppressing TLR2 expression. All the results suggested that miR-344b-1-3p decreased the phagocytic activity of AMs by suppressing NF-κB signaling pathway. TNF-α, IL-1β, and MIP-2 are important proinflammatory factors expressed by AMs and play an important role in the defense of the body against foreign pathogens, such as viruses, bacteria, and fungi. It has been reported that TNF-α plays a critical role in defending against Aspergillus by promoting the production of some inflammatory cytokines to activate immune responses, inducing the activation and recruitment of neutrophils, as well as increasing the level of superoxide dismutase and lysosomal enzymes, to facilitate clearance of Aspergillus. IL-1β is critically involved in the differentiation, maturation, and recruitment of inflammation cells, contributing to the host response against Aspergillus. MIP-2 could recruit neutrophils in the airway to protect from Aspergillus infection. Therefore, production of TNF-α, IL-1β, and MIP-2 was examined in this study to monitor the effects of miR-344b-1-3p on the TLR2-mediated inflammation. After transfection with miR-344b-1-3p inhibitor and exposure to Pam3CSK4, the levels of TNF-α, IL-1β, and MIP-2 secreted by NR8383 cells were determined. The data revealed that miR-344b-1-3p inhibitor significantly increased TNF-α, IL-1β, and MIP-2 expressions, which suggested that the downexpression of TLR2 in AMs contributed to the reduced TNF-α, IL-1β, and MIP-2 expressions in COPD AMs. Based on the study of Yang et al,28 TLR2 is capable of initiating the generation of reactive oxygen species (ROS) via an ASK1/p38 MAPK/p47phox cascade. Once activated, downstream signaling pathways will finally lead to the production of proinflammatory factors, including TNF-α, IL-1β, and MIP-2,29,30 which might explain the mechanism through which miR-344b-1-3p decreased the defense activity of AMs. A previous study suggested the important role of activated ERK in the defense against Aspergillus fumigatus by inducing the production of TNF-α through a TLR2-independent manner.31 However, we observed that the increased expression of TLR2 by miR-344b-1-3p inhibitor induced the activation of ERK. The inconsistency may be due to the different experiment systems between studies. In this study, NR8383 cells were exposed to CSE, while TLR2 and Myd88 knock out mice were used in the previous study. COPD induced by smoking not only suppressed the expression of TLR2 but also altered the biological property permanently. In this pathological status, the expression of TLR2 might play an important role in the defense against IPA. IRAK-1 is an important cytokine inducing the activation of NF-κB and proinflammatory responses.32 The increased p-IRAK-1 was observed after miR-344b-1-3p inhibition in this study. Taken together, it indicated that inhibition of TLR2 by the miRNA might play an important role in the pathogenesis of IPA by decreasing the activation of IRAK-1 and ERK. In addition, the impairments of smoking on the normal function of smokers are irreversible if proper treatments are not conducted. Therefore, patients with COPD suffer from inflammation and immune abnormalities even years after they quit smoking. However, whether these abnormalities are attributed to the dysexpression of miRNAs induced by smoking needs to be further explored with a long-term experiment.

Conclusion

Our data revealed that miR-344b-1-3p plays an important role in suppressing TLR2 expression and signaling, indicating that this miRNA functionally decreases the defense activity of AMs in COPD rats. TLR2 inhibition can impair host immune defenses against respiratory infections in smokers. This study suggested that miRNA-modulated TLR2 may be a preventive and therapeutic target for the treatment of IPA. However, further studies with COPD human participants will be required to comprehensively delineate the relative contribution of miRNAs to the sensitivity of COPD patients to Aspergillus.
  31 in total

Review 1.  Molecular pathogenesis of cigarette smoking-induced stable COPD.

Authors:  Gaetano Caramori; Paul Kirkham; Adam Barczyk; Antonino Di Stefano; Ian Adcock
Journal:  Ann N Y Acad Sci       Date:  2015-01-13       Impact factor: 5.691

2.  Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4.

Authors:  Marc Dubourdeau; Rafika Athman; Viviane Balloy; Michel Huerre; Michel Chignard; Dana J Philpott; Jean-Paul Latgé; Oumaïma Ibrahim-Granet
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

3.  Toll-like receptor expression in smokers with and without COPD.

Authors:  Ida von Scheele; Kjell Larsson; Barbro Dahlén; Bo Billing; Maria Skedinger; Ann-Sofie Lantz; Lena Palmberg
Journal:  Respir Med       Date:  2011-03-24       Impact factor: 3.415

4.  Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells.

Authors:  Sandra Hodge; Greg Hodge; Raffaele Scicchitano; Paul N Reynolds; Mark Holmes
Journal:  Immunol Cell Biol       Date:  2003-08       Impact factor: 5.126

5.  Modulation of TLR2 protein expression by miR-105 in human oral keratinocytes.

Authors:  Manjunatha R Benakanakere; Qiyan Li; Mehmet A Eskan; Amar V Singh; Jiawei Zhao; Johnah C Galicia; Panagiota Stathopoulou; Thomas B Knudsen; Denis F Kinane
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

Review 6.  Involvement of microRNAs in physiological and pathological processes in the lung.

Authors:  Tereza Tomankova; Martin Petrek; Eva Kriegova
Journal:  Respir Res       Date:  2010-11-23

7.  Toxicity Mechanisms of Cigarette Smoke on Mouse Fetus Mitochondria.

Authors:  Parvaneh Naserzadeh; Mir-Jamal Hosseini; Baharak Mohamadzadeh Asl; Jalal Pourahmad
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

Review 8.  MicroRNAs in inflammatory lung disease--master regulators or target practice?

Authors:  Irene K Oglesby; Noel G McElvaney; Catherine M Greene
Journal:  Respir Res       Date:  2010-10-28

9.  Roles of microRNA-146a and microRNA-181b in regulating the secretion of tumor necrosis factor-α and interleukin-1β in silicon dioxide-induced NR8383 rat macrophages.

Authors:  Yang Zhang; Faxuan Wang; Yajia Lan; Dinglun Zhou; Xiaohui Ren; Liqiang Zhao; Qin Zhang
Journal:  Mol Med Rep       Date:  2015-07-16       Impact factor: 2.952

10.  miR-1915 and miR-1225-5p regulate the expression of CD133, PAX2 and TLR2 in adult renal progenitor cells.

Authors:  Fabio Sallustio; Grazia Serino; Vincenzo Costantino; Claudia Curci; Sharon N Cox; Giuseppe De Palma; Francesco P Schena
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

View more
  5 in total

1.  microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus.

Authors:  Ke Xu; Dezhi Bian; Lanxiang Hao; Fei Huang; Min Xu; Jie Qin; Yanmei Liu
Journal:  EXCLI J       Date:  2017-10-27       Impact factor: 4.068

2.  Next-generation sequencing predicts interaction network between miRNA and target genes in lipoteichoic acid-stimulated human neutrophils.

Authors:  Meng-Chi Yen; I-Jeng Yeh; Kuan-Ting Liu; Shu-Fang Jian; Chia-Jung Lin; Ming-Ju Tsai; Po-Lin Kuo
Journal:  Int J Mol Med       Date:  2019-07-31       Impact factor: 4.101

3.  Identification of candidate genes and miRNAs associated with neuropathic pain induced by spared nerve injury.

Authors:  He Li; Hong-Quan Wan; Hai-Jun Zhao; Shu-Xin Luan; Chun-Guo Zhang
Journal:  Int J Mol Med       Date:  2019-08-06       Impact factor: 4.101

Review 4.  MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  José A Cañas; José M Rodrigo-Muñoz; Beatriz Sastre; Marta Gil-Martinez; Natalia Redondo; Victoria Del Pozo
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 5.  The miRNA: a small but powerful RNA for COVID-19.

Authors:  Song Zhang; Kuerbannisha Amahong; Xiuna Sun; Xichen Lian; Jin Liu; Huaicheng Sun; Yan Lou; Feng Zhu; Yunqing Qiu
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.